HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies

Colon cancer, one of the most common and fatal cancers worldwide, is characterized by stepwise accumulation of specific genetic alterations in tumor suppressor genes or oncogenes, leading to tumor growth and metastasis. HIPK2 (homeodomain-interacting protein kinase 2) is a serine/threonine protein k...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-07, Vol.25 (14), p.7678
Main Authors: Verdina, Alessandra, Garufi, Alessia, D'Orazi, Valerio, D'Orazi, Gabriella
Format: Article
Language:English
Subjects:
Angiogenesis
Apoptosis
Biomarkers
Cancer therapies
Cell cycle
Chemotherapy
Colon cancer
Colorectal cancer
Development and progression
Diabetes
Disease
DNA damage
Family medical history
Fibroblasts
Genomes
Growth factors
Health aspects
HIPK2
Hyperglycemia
Hypoxia
Inflammation
Kinases
Metastasis
Mortality
Mutation
p53
Protein kinases
Proteins
Tumor proteins
Tumorigenesis
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c377t-aceef469f77ff143ed3facc31751dd0fdfa83a88208cacad9b2abc006357fd723
container_end_page
container_issue 14
container_start_page 7678
container_title International journal of molecular sciences
container_volume 25
creator Verdina, Alessandra
Garufi, Alessia
D'Orazi, Valerio
D'Orazi, Gabriella
description Colon cancer, one of the most common and fatal cancers worldwide, is characterized by stepwise accumulation of specific genetic alterations in tumor suppressor genes or oncogenes, leading to tumor growth and metastasis. HIPK2 (homeodomain-interacting protein kinase 2) is a serine/threonine protein kinase and a "bona fide" oncosuppressor protein. Its activation inhibits tumor growth mainly by promoting apoptosis, while its inactivation increases tumorigenicity and resistance to therapies of many different cancer types, including colon cancer. HIPK2 interacts with many molecular pathways by means of its kinase activity or transcriptional co-repressor function modulating cell growth and apoptosis, invasion, angiogenesis, inflammation and hypoxia. HIPK2 has been shown to participate in several molecular pathways involved in colon cancer including p53, Wnt/β-catenin and the newly identified nuclear factor erythroid 2 (NF-E2) p45-related factor 2 (NRF2). HIPK2 also plays a role in tumor-host interaction in the tumor microenvironment (TME) by inducing angiogenesis and cancer-associated fibroblast (CAF) differentiation. The aim of this review is to assess the role of HIPK2 in colon cancer and the underlying molecular pathways for a better understanding of its involvement in colon cancer carcinogenesis and response to therapies, which will likely pave the way for novel colon cancer therapies.
doi_str_mv 10.3390/ijms25147678
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cb87fbce4f2f448e8ae10043060288f2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A803774079</galeid><doaj_id>oai_doaj_org_article_cb87fbce4f2f448e8ae10043060288f2</doaj_id><sourcerecordid>A803774079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-aceef469f77ff143ed3facc31751dd0fdfa83a88208cacad9b2abc006357fd723</originalsourceid><addsrcrecordid>eNptks1v1DAQxSNERUvhxhlZ4sKBLf5K7HBbVkBXrcQKLTcka-KMFy9JvNjJgf8ehy1tQZWssWX93vM8a4riBaMXQtT0rd_3iZdMqkrpR8UZk5wvKK3U43vn0-JpSntKueBl_aQ4zbqK15ydFd8u15srTvxAVqELucJgMb4jS7IJIw6jh46896GH-AMjcSGS7dTnuolhFzElnzUwtOQLpkMYEpIxkO13jHDwmJ4VJw66hM9v9vPi68cP29Xl4vrzp_Vqeb2wQqlxARbRyap2SjnHpMBWOLBWMFWytqWudaAFaM2ptmChrRsOjc25RKlcq7g4L9ZH3zbA3hyiz-3-MgG8-XMR4s5AHL3t0NhGK9dYlI47KTVqQEapFLSiXGs3e70-eh1i-DlhGk3vk8WugwHDlIygumRMSTajr_5D92GKQ046U7KWebE7agf5fT-4MEaws6lZapo_QFJVZ-riAWpOi723YUDn8_0_gjdHgY0hpYjuNjejZh4Mc38wMv7yptep6bG9hf9OgvgNhVixOw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3084944941</pqid></control><display><type>article</type><title>HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies</title><source>Open Access: PubMed Central</source><source>ProQuest - Publicly Available Content Database</source><creator>Verdina, Alessandra ; Garufi, Alessia ; D'Orazi, Valerio ; D'Orazi, Gabriella</creator><creatorcontrib>Verdina, Alessandra ; Garufi, Alessia ; D'Orazi, Valerio ; D'Orazi, Gabriella</creatorcontrib><description>Colon cancer, one of the most common and fatal cancers worldwide, is characterized by stepwise accumulation of specific genetic alterations in tumor suppressor genes or oncogenes, leading to tumor growth and metastasis. HIPK2 (homeodomain-interacting protein kinase 2) is a serine/threonine protein kinase and a "bona fide" oncosuppressor protein. Its activation inhibits tumor growth mainly by promoting apoptosis, while its inactivation increases tumorigenicity and resistance to therapies of many different cancer types, including colon cancer. HIPK2 interacts with many molecular pathways by means of its kinase activity or transcriptional co-repressor function modulating cell growth and apoptosis, invasion, angiogenesis, inflammation and hypoxia. HIPK2 has been shown to participate in several molecular pathways involved in colon cancer including p53, Wnt/β-catenin and the newly identified nuclear factor erythroid 2 (NF-E2) p45-related factor 2 (NRF2). HIPK2 also plays a role in tumor-host interaction in the tumor microenvironment (TME) by inducing angiogenesis and cancer-associated fibroblast (CAF) differentiation. The aim of this review is to assess the role of HIPK2 in colon cancer and the underlying molecular pathways for a better understanding of its involvement in colon cancer carcinogenesis and response to therapies, which will likely pave the way for novel colon cancer therapies.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms25147678</identifier><identifier>PMID: 39062921</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Angiogenesis ; Apoptosis ; Biomarkers ; Cancer therapies ; Cell cycle ; Chemotherapy ; Colon cancer ; Colorectal cancer ; Development and progression ; Diabetes ; Disease ; DNA damage ; Family medical history ; Fibroblasts ; Genomes ; Growth factors ; Health aspects ; HIPK2 ; Hyperglycemia ; Hypoxia ; Inflammation ; Kinases ; Metastasis ; Mortality ; Mutation ; p53 ; Protein kinases ; Proteins ; Tumor proteins ; Tumorigenesis ; Tumors</subject><ispartof>International journal of molecular sciences, 2024-07, Vol.25 (14), p.7678</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c377t-aceef469f77ff143ed3facc31751dd0fdfa83a88208cacad9b2abc006357fd723</cites><orcidid>0000-0001-9972-9237 ; 0000-0002-3535-180X ; 0000-0001-6876-9105</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3084944941/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3084944941?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39062921$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verdina, Alessandra</creatorcontrib><creatorcontrib>Garufi, Alessia</creatorcontrib><creatorcontrib>D'Orazi, Valerio</creatorcontrib><creatorcontrib>D'Orazi, Gabriella</creatorcontrib><title>HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Colon cancer, one of the most common and fatal cancers worldwide, is characterized by stepwise accumulation of specific genetic alterations in tumor suppressor genes or oncogenes, leading to tumor growth and metastasis. HIPK2 (homeodomain-interacting protein kinase 2) is a serine/threonine protein kinase and a "bona fide" oncosuppressor protein. Its activation inhibits tumor growth mainly by promoting apoptosis, while its inactivation increases tumorigenicity and resistance to therapies of many different cancer types, including colon cancer. HIPK2 interacts with many molecular pathways by means of its kinase activity or transcriptional co-repressor function modulating cell growth and apoptosis, invasion, angiogenesis, inflammation and hypoxia. HIPK2 has been shown to participate in several molecular pathways involved in colon cancer including p53, Wnt/β-catenin and the newly identified nuclear factor erythroid 2 (NF-E2) p45-related factor 2 (NRF2). HIPK2 also plays a role in tumor-host interaction in the tumor microenvironment (TME) by inducing angiogenesis and cancer-associated fibroblast (CAF) differentiation. The aim of this review is to assess the role of HIPK2 in colon cancer and the underlying molecular pathways for a better understanding of its involvement in colon cancer carcinogenesis and response to therapies, which will likely pave the way for novel colon cancer therapies.</description><subject>Angiogenesis</subject><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Chemotherapy</subject><subject>Colon cancer</subject><subject>Colorectal cancer</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Disease</subject><subject>DNA damage</subject><subject>Family medical history</subject><subject>Fibroblasts</subject><subject>Genomes</subject><subject>Growth factors</subject><subject>Health aspects</subject><subject>HIPK2</subject><subject>Hyperglycemia</subject><subject>Hypoxia</subject><subject>Inflammation</subject><subject>Kinases</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Mutation</subject><subject>p53</subject><subject>Protein kinases</subject><subject>Proteins</subject><subject>Tumor proteins</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks1v1DAQxSNERUvhxhlZ4sKBLf5K7HBbVkBXrcQKLTcka-KMFy9JvNjJgf8ehy1tQZWssWX93vM8a4riBaMXQtT0rd_3iZdMqkrpR8UZk5wvKK3U43vn0-JpSntKueBl_aQ4zbqK15ydFd8u15srTvxAVqELucJgMb4jS7IJIw6jh46896GH-AMjcSGS7dTnuolhFzElnzUwtOQLpkMYEpIxkO13jHDwmJ4VJw66hM9v9vPi68cP29Xl4vrzp_Vqeb2wQqlxARbRyap2SjnHpMBWOLBWMFWytqWudaAFaM2ptmChrRsOjc25RKlcq7g4L9ZH3zbA3hyiz-3-MgG8-XMR4s5AHL3t0NhGK9dYlI47KTVqQEapFLSiXGs3e70-eh1i-DlhGk3vk8WugwHDlIygumRMSTajr_5D92GKQ046U7KWebE7agf5fT-4MEaws6lZapo_QFJVZ-riAWpOi723YUDn8_0_gjdHgY0hpYjuNjejZh4Mc38wMv7yptep6bG9hf9OgvgNhVixOw</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Verdina, Alessandra</creator><creator>Garufi, Alessia</creator><creator>D'Orazi, Valerio</creator><creator>D'Orazi, Gabriella</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9972-9237</orcidid><orcidid>https://orcid.org/0000-0002-3535-180X</orcidid><orcidid>https://orcid.org/0000-0001-6876-9105</orcidid></search><sort><creationdate>20240701</creationdate><title>HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies</title><author>Verdina, Alessandra ; Garufi, Alessia ; D'Orazi, Valerio ; D'Orazi, Gabriella</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-aceef469f77ff143ed3facc31751dd0fdfa83a88208cacad9b2abc006357fd723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Angiogenesis</topic><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Chemotherapy</topic><topic>Colon cancer</topic><topic>Colorectal cancer</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Disease</topic><topic>DNA damage</topic><topic>Family medical history</topic><topic>Fibroblasts</topic><topic>Genomes</topic><topic>Growth factors</topic><topic>Health aspects</topic><topic>HIPK2</topic><topic>Hyperglycemia</topic><topic>Hypoxia</topic><topic>Inflammation</topic><topic>Kinases</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Mutation</topic><topic>p53</topic><topic>Protein kinases</topic><topic>Proteins</topic><topic>Tumor proteins</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verdina, Alessandra</creatorcontrib><creatorcontrib>Garufi, Alessia</creatorcontrib><creatorcontrib>D'Orazi, Valerio</creatorcontrib><creatorcontrib>D'Orazi, Gabriella</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verdina, Alessandra</au><au>Garufi, Alessia</au><au>D'Orazi, Valerio</au><au>D'Orazi, Gabriella</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>25</volume><issue>14</issue><spage>7678</spage><pages>7678-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Colon cancer, one of the most common and fatal cancers worldwide, is characterized by stepwise accumulation of specific genetic alterations in tumor suppressor genes or oncogenes, leading to tumor growth and metastasis. HIPK2 (homeodomain-interacting protein kinase 2) is a serine/threonine protein kinase and a "bona fide" oncosuppressor protein. Its activation inhibits tumor growth mainly by promoting apoptosis, while its inactivation increases tumorigenicity and resistance to therapies of many different cancer types, including colon cancer. HIPK2 interacts with many molecular pathways by means of its kinase activity or transcriptional co-repressor function modulating cell growth and apoptosis, invasion, angiogenesis, inflammation and hypoxia. HIPK2 has been shown to participate in several molecular pathways involved in colon cancer including p53, Wnt/β-catenin and the newly identified nuclear factor erythroid 2 (NF-E2) p45-related factor 2 (NRF2). HIPK2 also plays a role in tumor-host interaction in the tumor microenvironment (TME) by inducing angiogenesis and cancer-associated fibroblast (CAF) differentiation. The aim of this review is to assess the role of HIPK2 in colon cancer and the underlying molecular pathways for a better understanding of its involvement in colon cancer carcinogenesis and response to therapies, which will likely pave the way for novel colon cancer therapies.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39062921</pmid><doi>10.3390/ijms25147678</doi><orcidid>https://orcid.org/0000-0001-9972-9237</orcidid><orcidid>https://orcid.org/0000-0002-3535-180X</orcidid><orcidid>https://orcid.org/0000-0001-6876-9105</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2024-07, Vol.25 (14), p.7678
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_cb87fbce4f2f448e8ae10043060288f2
source Open Access: PubMed Central; ProQuest - Publicly Available Content Database
subjects Angiogenesis
Apoptosis
Biomarkers
Cancer therapies
Cell cycle
Chemotherapy
Colon cancer
Colorectal cancer
Development and progression
Diabetes
Disease
DNA damage
Family medical history
Fibroblasts
Genomes
Growth factors
Health aspects
HIPK2
Hyperglycemia
Hypoxia
Inflammation
Kinases
Metastasis
Mortality
Mutation
p53
Protein kinases
Proteins
Tumor proteins
Tumorigenesis
Tumors
title HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A47%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HIPK2%20in%20Colon%20Cancer:%20A%20Potential%20Biomarker%20for%20Tumor%20Progression%20and%20Response%20to%20Therapies&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Verdina,%20Alessandra&rft.date=2024-07-01&rft.volume=25&rft.issue=14&rft.spage=7678&rft.pages=7678-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms25147678&rft_dat=%3Cgale_doaj_%3EA803774079%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c377t-aceef469f77ff143ed3facc31751dd0fdfa83a88208cacad9b2abc006357fd723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3084944941&rft_id=info:pmid/39062921&rft_galeid=A803774079&rfr_iscdi=true